Business Wire

Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660

Share

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) issued a positive vote for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005907/en/

VRBPAC voted 13 to 4 that the data were adequate to support the effectiveness of RBX2660 to reduce the recurrence of CDI in adults 18 years of age and older following antibiotic treatment for recurrent CDI. The Committee also voted 12 to 4 with 1 abstention that the data were adequate to support the safety of RBX2660 when administered to adults 18 years of age and older following antibiotic treatment for recurrent CDI. The advisory committee provides recommendations to the FDA, which the agency may consider but is not required to follow, when making its decision.

“Patients with recurrent C. difficile infection currently have limited treatment options,” said Paul Feuerstadt, MD, FACG, AGAF, Yale University School of Medicine.“The committee’s vote is a step toward potentially addressing the debilitating cycle of recurrence and the suffering faced by these patients.”

The committee reviewed data from the biologics license application (BLA) for RBX2660. The clinical development program for RBX2660 included six studies with a total of 1061 participants, of which 978 were treated with RBX2660.

“Today’s advisory committee vote represents an important milestone in Ferring’s ongoing efforts to address the unmet need for interventions that can reduce the incidence of recurrent C. difficile infection, which represents a significant health burden for patients,” said Mirjam Mol-Arts, Executive Vice President, Chief Medical Officer, Ferring Pharmaceuticals.

About C. difficile infection
C. difficile infection (CDI) is a serious and potentially deadly disease that impacts people across the globe. The C. difficile bacterium causes debilitating symptoms such as severe diarrhea, fever, stomach tenderness or pain, loss of appetite, nausea, and colitis (an inflammation of the colon).1 Declared a public health threat by the U.S. Centers for Disease Control and Prevention (CDC) requiring urgent and immediate action, CDI causes an estimated half a million illnesses and tens of thousands of deaths in the U.S. alone each year.1,2,3

C. difficile infection often is the start of a vicious cycle of recurrence, causing a significant burden for patients and the healthcare system.4,5 It has been estimated that up to 35% of CDI cases recur after initial diagnosis and people who have had a recurrence are at significantly higher risk of further infections.6,7,8,9 After the first recurrence, it has been estimated that up to 65% of patients may develop a subsequent recurrence.8,9

About RBX2660
RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection after antibiotic treatment. RBX2660 has been granted Fast Track, Orphan, and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA). RBX2660 was developed by Rebiotix, a Ferring company.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in more than 50 countries, and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. Ferring is working to develop novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. Connect with us on our dedicated microbiome therapeutics development channels on Twitter and LinkedIn.

References:

  1. Centers for Disease Control and Prevention. What Is C. Diff? 17 Dec. 2018. Available at: https://www.cdc.gov/cdiff/what-is.html.
  2. Centers for Disease Control and Prevention. Biggest Threats and Data, 14 Nov. 2019. Available at: https://www.cdc.gov/drugresistance/biggest-threats.html
  3. Fitzpatrick F, Barbut F. Breaking the cycle of recurrent Clostridium difficile. Clin Microbiol Infect. 2012;18(suppl 6):2-4.
  4. Centers for Disease Control and Prevention. 24 June 2020. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/clostridioides-difficile-508.pdf.
  5. Feuerstadt P, et al. J Med Econ. 2020;23(6):603-609.
  6. Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am. 2009;23(3):727-743.
  7. Nelson WW, et al. Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis. J Manag Care Spec Pharm. Published online March 11, 2021.
  8. Kelly, CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012; 18 (Suppl. 6): 21–27.
  9. Smits WK, et al. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020. doi: 10.1038/nrdp.2016.20.
  10. Leong C, Zelenitsky S. Treatment strategies for recurrent Clostridium difficile infection. Can J Hosp Pharm. 2013;66(6):361-368.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lisa Ellen
Director, Brand Communications
+1-862-286-5696 (direct)
lisa.ellen@ferring.com

Carine Julen
Corporate Communications Manager
+41-76-301-0178
carine.julen@ferring.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Generac Power Systems and EODev Announce Agreement Bringing Large-Scale, Zero-Emissions Hydrogen Fuel Cell Power Generators to North America3.10.2022 19:44:00 CEST | Press release

Generac Power Systems (NYSE: GNRC), a leading global designer and manufacturer of energy technology solutions and other power products, and EODev, a French developer and manufacturer of zero-emission hydrogen fuel cell power generators, today announced a formal distribution agreement. Generac will offer EODev’s GEH2® – a large-scale, zero-emissions hydrogen fuel cell power generator – to the North American market. The distribution agreement signifies the continued growth and availability of alternative energy solutions for the industrial power sector, which addresses a pioneering market in the transition to low-carbon and emission-free power solutions. This collaboration emphasizes Generac’s Powering A Smarter World strategic focus and equally expands EODev’s presence in the North American market with its cutting-edge, one-of-a-kind hydrogen fuel cell power generators. Generac has placed an initial order for the GEH2® generators, some of which have already arrived in the United States.

Enviva Releases White Paper on the Evolution of Modern Bioenergy in Heavy Industry Verticals3.10.2022 18:00:00 CEST | Press release

Today, Enviva Inc. (NYSE: EVA), the world’s leading producer of sustainably sourced wood biomass, published a white paper that discusses unlocking the future of biomass beyond fossil fuels into other industrial applications, including steel, cement, lime, chemicals, and sustainable aviation fuel (SAF), among others. While Enviva’s sustainably sourced biomass is predominately used today to decarbonize power and heat generation, modern biomass will increasingly be used to reduce emissions in these hard-to-abate sectors that are responsible for nearly one-third of global CO2 emissions as governments, companies, and industry endeavor to mitigate their climate change impacts through net-zero emissions goals. All sectors ‒ including energy, construction, transportation, aviation, and food systems ‒ are looking to rapidly decarbonize, and sustainably sourced biomass is the only technologically advanced, scalable, and market-ready product poised to substantially mitigate climate change and dec

DentalMonitoring Expands into Japan3.10.2022 17:53:00 CEST | Press release

New office in Tokyo; bringing smarter dentistry solutions to Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221003005816/en/ DentalMonitoring ScanBox pro (Photo: Business Wire) DentalMonitoring, the leading global provider of smart dentistry solutions, is setting foot in Japan to serve the Asian market with its AI-powered remote monitoring solution and latest clinical data analysis platform DM Insights. Having been granted market authorization, the company headquartered in Paris, France, is now bringing its suite of intelligent solutions onto the Japanese market. From lead engagement and conversion to remote monitoring of all treatment modalities, DentalMonitoring has helped transform over 7,000 practices worldwide and over 1 million patients have already been using its ScanBoxᵖʳᵒ and 4.9 rated app, helping optimize their treatment experience. ScanBoxᵖʳᵒ will be available from Dental Monitoring Japan in October 2022.

AIT Worldwide Logistics Forms CRAF Partnership with Kalitta Air3.10.2022 17:02:00 CEST | Press release

Global supply chain solutions leader AIT Worldwide Logistics has entered into a new Civil Reserve Air Fleet (CRAF) partnership with Ypsilanti, Michigan-based Kalitta Air. The strategic alliance continues AIT’s longstanding designation as a CRAF-sponsored freight forwarder, enabling the company to continue critical supply chain support for United States Transportation Command (USTRANSCOM) missions, while also increasing access to global routes, capacity, and charters for customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221003005635/en/ AIT Worldwide Logistics forms CRAF partnership with Kalitta Air (Photo: Business Wire) “For more than 10 years, we’ve been proud and always at the ready to support USTRANSCOM through the CRAF program,” said AIT’s Chief Business Officer, Greg Weigel. “As AIT continues to grow our global footprint and scope, securing a CRAF partnership with an airline that has similar global reach, with

Survey Reveals Tech Trust Gap Amongst UK Bank Customers3.10.2022 15:38:00 CEST | Press release

New research by Mitek, a global leader in digital identity and digital fraud prevention, and YouGov has found that banking customers’ trust in technology remains low in the United Kingdom. Only half (52%) of UK bank customers feel that technology like artificial intelligence (AI) and biometrics positively impacts their trust in banks, and only 5% would prefer all interactions with AI/automated systems when engaging banks. These findings are based on a survey of more than 2,200 adults across age groups and UK regions. The industry has undergone a rapid digital transformation in the last few years, with Gartner predicting IT spending by banking and investment services firms growing by 6.1% by end of 2022, to US$623 billion worldwide. While nearly eight in 10 (79%) customers are satisfied with their bank’s digital experience (rating it “good”, “very good”, “or “excellent”), banks are in danger of facing a market-driven stalemate in their research and development should the tech trust gap

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom